Alnylam Pharmaceuticals (ALNY) Depreciation & Amortization (CF) (2009 - 2026)

Alnylam Pharmaceuticals has reported Depreciation & Amortization (CF) for 18 years, with the latest figure at $13.6 million in Q1 2026.

• For the quarter ending Q1 2026, Depreciation & Amortization (CF) fell 5.91% year-over-year to $13.6 million; the trailing twelve-month figure through Mar 2026 stood at $54.8 million (down 4.78% YoY), and the FY2025 full-year result was $55.7 million, down 1.79% from the prior year.
• Depreciation & Amortization (CF) for Q1 2026 stood at $13.6 million, roughly flat from $13.5 million in the prior quarter.
• The five-year high for Depreciation & Amortization (CF) was $15.0 million in Q2 2024, with the low at $9.5 million in Q1 2022.
• Historically, Depreciation & Amortization (CF) has averaged $13.2 million across 5 years, with a median of $13.6 million in 2026.
• Annual changes were most pronounced in 2022 — Depreciation & Amortization (CF) slipped 24.93% — and 2023, when it soared 48.68%.
• Alnylam Pharmaceuticals' Depreciation & Amortization (CF) stood at $14.3 million in 2022, then declined by 5.79% to $13.5 million in 2023, then advanced by 5.09% to $14.2 million in 2024, then fell by 4.67% to $13.5 million in 2025, then grew by 0.35% to $13.6 million in 2026.
• The last three Depreciation & Amortization (CF) figures came in at $13.6 million (Q1 2026), $13.5 million (Q4 2025), and $13.8 million (Q3 2025), per Business Quant data.